A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. by Satish Keshav, Tomáš Vaňásek, Yaron Niv, Robert Petryka, Stephanie Howaldt, Mauro Bafutto, István Rácz, David Hetzel, Ole Haagen Nielsen, Séverine Vermeire, Walter Reinisch, Per Karlén, Stefan Schreiber, Thomas J Schall, Pirow Bekker, Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group

Get full text